Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 10Colorectal Neoplasms 5Stomach Neoplasms 3Rhabdomyosarcoma 3Osteosarcoma 3Biliary Tract Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Wilms Tumor 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Cancer Patients 1Peritoneal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Metastatic Gastric Adenocarcinoma 1Metastatic Adenocarcinoma of the Pancreas 1Malignant Ascites 1Hepatoblastoma 1Gastrointestinal Neoplasms 1Gastroesophageal Junction Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Paclitaxel 15Carboplatin 9liposomal doxorubicin 8Bevacizumab 8pembrolizumab 7Topotecan 6olaparib 4mirvetuximab soravtansine 4Nivolumab 4Cyclophosphamide 4niraparib 3fludarabine 3Gemcitabine 3Drug Therapy 3rucaparib 2ribociclib 2pegfilgrastim 2palbociclib 2oregovomab 2fludarabine phosphate 2Irinotecan 2Hyperthermic Intraperitoneal Chemotherapy 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 21-dodecylpyridoxal 2trastuzumab deruxtecan 1sacituzumab govitecan 1isoquercitrin 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × irinotecan sucrosofate × 1 year × Clear all
NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡